AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics https://www.bioworld.com/rss en-us ADCs’ breakout 2025 and their still-unfinished potential http://www.bioworld.com/articles/727720 Fri, 02 Jan 2026 08:00:00 -0500 https://www.bioworld.com/articles/727720-adcs-breakout-2025-and-their-still-unfinished-potential 3D rendering of antibody drug conjugated with cytotoxic payload ADCs’ breakout 2025 and their still-unfinished potential http://www.bioworld.com/articles/727478 Tue, 30 Dec 2025 08:00:00 -0500 https://www.bioworld.com/articles/727478-adcs-breakout-2025-and-their-still-unfinished-potential 3D rendering of antibody drug conjugated with cytotoxic payload New FGFR3 inhibitors offer best-in-class selectivity, potency http://www.bioworld.com/articles/726572 Wed, 26 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726572-new-fgfr3-inhibitors-offer-best-in-class-selectivity-potency Bladder Selective CDK2 inhibitor is active in multiple solid tumor models http://www.bioworld.com/articles/726528 Mon, 24 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726528-selective-cdk2-inhibitor-is-active-in-multiple-solid-tumor-models Targeted cancer cell Small-molecule SMARCA2 inhibitors to treat SMARCA4-mutant cancers http://www.bioworld.com/articles/726526 Mon, 24 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726526-small-molecule-smarca2-inhibitors-to-treat-smarca4-mutant-cancers Novel B7-H7-targeted ADC NPX-125 active in solid tumors http://www.bioworld.com/articles/726413 Fri, 21 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726413-novel-b7-h7-targeted-adc-npx-125-active-in-solid-tumors EP-102 METTL3 inhibitor shows efficacy in NSCLC models http://www.bioworld.com/articles/726360 Thu, 20 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726360-ep-102-mettl3-inhibitor-shows-efficacy-in-nsclc-models Lung cancer illustration Oral cyclin D1-selective inhibitors with antitumor activity, improved safety profile http://www.bioworld.com/articles/726303 Wed, 19 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726303-oral-cyclin-d1-selective-inhibitors-with-antitumor-activity-improved-safety-profile Microscope with laptop displaying histology image. CEACAM5-targeting ADC with a highly potent pan-RAS(ON) inhibitor payload http://www.bioworld.com/articles/726287 Tue, 18 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726287-ceacam5-targeting-adc-with-a-highly-potent-pan-rason-inhibitor-payload Floating antibody drug conjugates Small-molecule p53 Y220C reactivators with enhanced potency presented http://www.bioworld.com/articles/726285 Tue, 18 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726285-small-molecule-p53-y220c-reactivators-with-enhanced-potency-presented RVU-305 shows potential against GBM in preclinical studies http://www.bioworld.com/articles/726283 Tue, 18 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726283-rvu-305-shows-potential-against-gbm-in-preclinical-studies AB-801 enhances KRAS inhibitor antitumor activity http://www.bioworld.com/articles/726085 Mon, 17 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726085-ab-801-enhances-kras-inhibitor-antitumor-activity 3D illustration of cancer in crosshairs CDK2 degraders show activity in HR+/HER2- and CCNE1-amplified breast tumors http://www.bioworld.com/articles/726066 Fri, 14 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726066-cdk2-degraders-show-activity-in-hr-her2-and-ccne1-amplified-breast-tumors Breast cancer illustration Macrocyclic KIF18A inhibitors show preclinical promise http://www.bioworld.com/articles/726003 Fri, 14 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726003-macrocyclic-kif18a-inhibitors-show-preclinical-promise Blue cancer cell HMPL-A251 combines HER2 targeting with precision payload http://www.bioworld.com/articles/725997 Fri, 14 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725997-hmpl-a251-combines-her2-targeting-with-precision-payload Concept art of an antibody-drug conjugate CBO-001, a first-in-class L1CAM ADC with preclinical antitumor activity http://www.bioworld.com/articles/726039 Thu, 13 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726039-cbo-001-a-first-in-class-l1cam-adc-with-preclinical-antitumor-activity Antibodies attacking cancer cell ITGB6-targeted ADC shows antitumor activity in solid tumor models http://www.bioworld.com/articles/726037 Thu, 13 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726037-itgb6-targeted-adc-shows-antitumor-activity-in-solid-tumor-models New oral KRAS G12C(ON) and G12V(ON) inhibitors presented http://www.bioworld.com/articles/726019 Wed, 12 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726019-new-oral-kras-g12con-and-g12von-inhibitors-presented Oral CBL-B inhibitor shows strong immune activation, favorable safety http://www.bioworld.com/articles/726018 Wed, 12 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726018-oral-cbl-b-inhibitor-shows-strong-immune-activation-favorable-safety Cancer immunotherapy illustration TRI-611 targets ALK fusion and TKI-resistant NSCLC http://www.bioworld.com/articles/726061 Tue, 11 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/726061-tri-611-targets-alk-fusion-and-tki-resistant-nsclc Illustration of lungs with cancer inset MGC-026, a B7-H3-targeted ADC with potent activity in prostate cancer models http://www.bioworld.com/articles/725932 Mon, 10 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725932-mgc-026-a-b7-h3-targeted-adc-with-potent-activity-in-prostate-cancer-models ZE77-0273 shows broad activity against EGFR resistance mutations in NSCLC http://www.bioworld.com/articles/725930 Mon, 10 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725930-ze77-0273-shows-broad-activity-against-egfr-resistance-mutations-in-nsclc 3D illustration and light micrograph of lung cancer. Discovery of PSTA-2413, a potential best-in-class oral pan-RAS inhibitor http://www.bioworld.com/articles/725929 Mon, 10 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725929-discovery-of-psta-2413-a-potential-best-in-class-oral-pan-ras-inhibitor Qurient presents data on QP-101, a dual-payload HER2-targeting ADC http://www.bioworld.com/articles/725912 Fri, 07 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725912-qurient-presents-data-on-qp-101-a-dual-payload-her2-targeting-adc Lab glassware and antibodies art concept MT-4561 exerts antitumor efficacy in NUT carcinoma http://www.bioworld.com/articles/725910 Fri, 07 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725910-mt-4561-exerts-antitumor-efficacy-in-nut-carcinoma Acrivon Therapeutics reports preclinical data on ACR-2316 http://www.bioworld.com/articles/725856 Thu, 06 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725856-acrivon-therapeutics-reports-preclinical-data-on-acr-2316 Cancer cell in the cross-hairs Accutar presents development of PI3Kα degrader-antibody conjugates http://www.bioworld.com/articles/725855 Thu, 06 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725855-accutar-presents-development-of-pi3k-degrader-antibody-conjugates CBB-120 shows potent TROP2 targeting with improved safety margin http://www.bioworld.com/articles/725851 Thu, 06 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725851-cbb-120-shows-potent-trop2-targeting-with-improved-safety-margin 3D rendering of an antibody-drug conjugate Bispecific antibody-drug conjugate Gensci-143 shows promise in solid tumors http://www.bioworld.com/articles/725837 Wed, 05 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725837-bispecific-antibody-drug-conjugate-gensci-143-shows-promise-in-solid-tumors 3D illustration demonstrating antibody-drug conjugate. Glycan-targeting ADC shows preclinical activity against HER2-low gastric cancer http://www.bioworld.com/articles/725835 Wed, 05 Nov 2025 08:00:00 -0500 https://www.bioworld.com/articles/725835-glycan-targeting-adc-shows-preclinical-activity-against-her2-low-gastric-cancer